NASDAQ:TXMDTherapeuticsMD Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding TherapeuticsMD Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.93 +0.01 (+1.09 %) (As of 04/7/2020 08:33 AM ET) Add Compare Share Today's Range$0.90Now: $0.93▼$0.9850-Day Range$0.92MA: $1.50▼$2.4852-Week Range$0.90Now: $0.93▼$4.97Volume2.71 million shsAverage Volume4.25 million shsMarket Capitalization$251.46 millionP/E RatioN/ADividend YieldN/ABeta1.94 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media TherapeuticsMD, Inc. operates as a women's health care product company in the United States. The company's hormone therapy drug candidate is the TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. Its preclinical projects include the development of TX-005HR, a topical progesterone cream; TX-006HR, an estradiol and progesterone topical cream to penetrate human skin; and TX-00THR and TX-0008HR, which are transdermal patch forms. The company also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. In addition, it commercializes IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. The company sells its prescription prenatal vitamin and hormone therapy drug products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingTherapeuticsMD has received a consensus rating of Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.00, TherapeuticsMD has a potential upside of 871.8% from its current price of $0.93.Amount of Analyst CoverageTherapeuticsMD has only been the subject of 2 research reports in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesTherapeuticsMD has received 355 “outperform” votes. (Add your “outperform” vote.)Underperform VotesTherapeuticsMD has received 318 “underperform” votes. (Add your “underperform” vote.)Community SentimentTherapeuticsMD has received 52.75% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about TherapeuticsMD and other stocks. Vote “Outperform” if you believe TXMD will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TXMD will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldTherapeuticsMD does not currently pay a dividend.Dividend GrowthTherapeuticsMD does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, TherapeuticsMD insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 18.91% of the stock of TherapeuticsMD is held by insiders.Percentage Held by Institutions70.88% of the stock of TherapeuticsMD is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for TherapeuticsMD are expected to decrease by -66.67% in the coming year, from ($0.63) to ($0.21) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TherapeuticsMD is -1.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of TherapeuticsMD is -1.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTherapeuticsMD has a P/B Ratio of 30.87. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.41 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TXMD Previous SymbolNYSEMKT:TXMD CUSIPN/A CIK25743 Webhttp://www.therapeuticsmd.com/ Phone561-961-1900Debt Debt-to-Equity Ratio22.15 Current Ratio3.93 Quick Ratio3.71Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$49.65 million Price / Sales5.06 Cash FlowN/A Price / Cash FlowN/A Book Value$0.03 per share Price / Book30.87Profitability EPS (Most Recent Fiscal Year)($0.68) Net Income$-176,150,000.00 Net Margins-354.79% Return on Equity-1,170.63% Return on Assets-70.36%Miscellaneous Employees241 Outstanding Shares271,530,000Market Cap$251.46 million Next Earnings Date5/4/2020 (Estimated) OptionableOptionable Receive TXMD News and Ratings via Email Sign-up to receive the latest news and ratings for TXMD and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:TXMD Rates by TradingView TherapeuticsMD (NASDAQ:TXMD) Frequently Asked Questions How has TherapeuticsMD's stock been impacted by COVID-19 (Coronavirus)? TherapeuticsMD's stock was trading at $1.52 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, TXMD shares have decreased by 39.1% and is now trading at $0.9261. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of TherapeuticsMD? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TherapeuticsMD in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for TherapeuticsMD. When is TherapeuticsMD's next earnings date? TherapeuticsMD is scheduled to release its next quarterly earnings announcement on Monday, May 4th 2020. View our earnings forecast for TherapeuticsMD. How were TherapeuticsMD's earnings last quarter? TherapeuticsMD Inc (NASDAQ:TXMD) released its quarterly earnings results on Thursday, February, 20th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.01. The firm had revenue of $15.90 million for the quarter, compared to the consensus estimate of $12.82 million. TherapeuticsMD had a negative net margin of 354.79% and a negative return on equity of 1,170.63%. TherapeuticsMD's revenue was up 212.4% on a year-over-year basis. During the same quarter last year, the firm posted ($0.17) earnings per share. View TherapeuticsMD's earnings history. What guidance has TherapeuticsMD issued on next quarter's earnings? TherapeuticsMD issued an update on its first quarter 2020 After-Hours earnings guidance on Thursday, March, 26th. The company provided EPS guidance of for the period. The company issued revenue guidance of $11 million, compared to the consensus revenue estimate of $11.64 million. What price target have analysts set for TXMD? 9 brokerages have issued 1-year price objectives for TherapeuticsMD's stock. Their forecasts range from $3.00 to $17.00. On average, they anticipate TherapeuticsMD's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 871.8% from the stock's current price. View analysts' price targets for TherapeuticsMD. Has TherapeuticsMD been receiving favorable news coverage? News coverage about TXMD stock has been trending very negative this week, InfoTrie reports. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. TherapeuticsMD earned a news impact score of -3.3 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutTherapeuticsMD. Who are some of TherapeuticsMD's key competitors? Some companies that are related to TherapeuticsMD include Kiniksa Pharmaceuticals (KNSA), TG Therapeutics (TGTX), I-Mab (ARQT), NextCure (NXTC), Phibro Animal Health (PAHC), Y-mAbs Therapeutics (YMAB), Madrigal Pharmaceuticals (MDGL), Supernus Pharmaceuticals (SUPN), Akebia Therapeutics (AKBA), Phathom Pharmaceuticals (PHAT), Amneal Pharmaceuticals (AMRX), Esperion Therapeutics (ESPR), Aimmune Therapeutics (AIMT), Phoenix Tree (IMAB) and Intra-Cellular Therapies (ITCI). What other stocks do shareholders of TherapeuticsMD own? Based on aggregate information from My MarketBeat watchlists, some companies that other TherapeuticsMD investors own include Opko Health (OPK), Verastem (VSTM), Teva Pharmaceutical Industries (TEVA), NVIDIA (NVDA), Cleveland-Cliffs (CLF), CannTrust (CNTTF), Inovio Pharmaceuticals (INO), Horizon Therapeutics (HZNP), Micron Technology (MU) and Novavax (NVAX). Who are TherapeuticsMD's key executives? TherapeuticsMD's management team includes the following people: Mr. Robert G. Finizio, Co-Founder, CEO & Director (Age 48)Mr. John C. K. Milligan IV, Pres, Sec. & Director (Age 57)Dr. Brian A. Bernick, Co-Founder, Chief Clinical Officer & Director (Age 51)Mr. Daniel Alan Cartwright, CFO & Treasurer (Age 61)Mr. Mitchell L. Krassan, Exec. VP & Chief Strategy Officer (Age 53) What is TherapeuticsMD's stock symbol? TherapeuticsMD trades on the NASDAQ under the ticker symbol "TXMD." How do I buy shares of TherapeuticsMD? Shares of TXMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is TherapeuticsMD's stock price today? One share of TXMD stock can currently be purchased for approximately $0.93. How big of a company is TherapeuticsMD? TherapeuticsMD has a market capitalization of $251.46 million and generates $49.65 million in revenue each year. The company earns $-176,150,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis. TherapeuticsMD employs 241 workers across the globe. View additional information about TherapeuticsMD. What is TherapeuticsMD's official website? The official website for TherapeuticsMD is http://www.therapeuticsmd.com/. How can I contact TherapeuticsMD? TherapeuticsMD's mailing address is 951 Yamato Road Suite 220, BOCA RATON FL, 33431. The company can be reached via phone at 561-961-1900 or via email at [email protected] This page was last updated on 4/7/2020 by MarketBeat.com StaffFeatured Article: Understanding debt-to-equity ratio in fundamental analysis
